Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
18.45
-0.56 (-2.95%)
May 15, 2026, 10:47 AM EDT - Market open
Avalo Therapeutics Revenue
Avalo Therapeutics had revenue of $59.00K in the twelve months ending March 31, 2026, down -86.62% year-over-year. In the year 2025, Avalo Therapeutics had annual revenue of $59.00K, down -86.62%.
Revenue (ttm)
$59.00K
Revenue Growth
-86.62%
P/S Ratio
8,607.45
Revenue / Employee
$1,788
Employees
33
Market Cap
492.88M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 59.00K | -382.00K | -86.62% |
| Dec 31, 2024 | 441.00K | -1.48M | -77.08% |
| Dec 31, 2023 | 1.92M | -16.13M | -89.34% |
| Dec 31, 2022 | 18.05M | 12.65M | 234.40% |
| Dec 31, 2021 | 5.40M | -1.30M | -19.42% |
| Dec 31, 2020 | 6.70M | -51.35K | -0.76% |
| Dec 31, 2019 | 6.75M | -278.03K | -3.96% |
| Dec 31, 2018 | 7.03M | -20.78M | -74.73% |
| Dec 31, 2017 | 27.81M | 26.66M | 2,312.26% |
| Dec 31, 2016 | 1.15M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | 82.76K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MiMedx Group | 389.42M |
| Ginkgo Bioworks Holdings | 151.40M |
| 4D Molecular Therapeutics | 88.24M |
| Prothena Corporation | 57.94M |
| XOMA Royalty | 48.56M |
| Ovid Therapeutics | 7.12M |
| Ocugen | 4.47M |
| Shattuck Labs | 1.00M |
AVTX News
- 21 hours ago - Avalo Therapeutics price target lowered to $34 from $40 at Wedbush - TheFly
- 1 day ago - Avalo Therapeutics price target raised to $45 from $39 at Mizuho - TheFly
- 1 day ago - Avalo Therapeutics price target lowered to $35 from $40 at H.C. Wainwright - TheFly
- 1 day ago - Avalo Therapeutics price target lowered to $55 from $62 at Citizens - TheFly
- 2 days ago - Avalo Therapeutics reports Q1 EPS (98c), consensus ($1.01) - TheFly
- 2 days ago - Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates - GlobeNewsWire
- 4 days ago - Avalo Therapeutics price target raised to $60 from $48 at Piper Sandler - TheFly
- 8 days ago - Avalo Therapeutics price target raised to $62 from $52 at Citizens - TheFly